Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "Glenmark-Pharma"

109 News Found

Glenmark launches Triple FDC of Teneligliptin with Pioglitazone and Metformin for adults with Type 2 Diabetes
News | December 22, 2022

Glenmark launches Triple FDC of Teneligliptin with Pioglitazone and Metformin for adults with Type 2 Diabetes

This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation


JB Pharma to buy Glenmark's ‘Razel’ for Rs. 314 crore in India and Nepal
News | December 14, 2022

JB Pharma to buy Glenmark's ‘Razel’ for Rs. 314 crore in India and Nepal

The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy


USFDA issues warning letter to Glenmark's Goa manufacturing facility
News | November 24, 2022

USFDA issues warning letter to Glenmark's Goa manufacturing facility

The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility


Glenmark receives ANDA approval for Sodium Phenylbutyrate Tablets
Drug Approval | November 03, 2022

Glenmark receives ANDA approval for Sodium Phenylbutyrate Tablets

Glenmark’s Sodium Phenylbutyrate Tablets USP, 500 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals USA.


Glenmark launches Zita D for adults with Type 2 diabetes having comorbidities
News | October 21, 2022

Glenmark launches Zita D for adults with Type 2 diabetes having comorbidities

A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities


Glenmark launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in adults
News | October 07, 2022

Glenmark launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in adults

Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).


Bausch and Glenmark announce approval of RYALTRIS in Canada
Drug Approval | September 24, 2022

Bausch and Glenmark announce approval of RYALTRIS in Canada

RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray


Hikma launches seasonal allergic rhinitis nasal spray RYALTRIS in the US
News | August 31, 2022

Hikma launches seasonal allergic rhinitis nasal spray RYALTRIS in the US

This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US


Glenmark receives OAI from USFDA for Goa facility
News | August 28, 2022

Glenmark receives OAI from USFDA for Goa facility

Glenmark continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest.


Glenmark  receives OAI communication from US FDA
Drug Approval | August 24, 2022

Glenmark receives OAI communication from US FDA

The company continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest